Haoyang Yu
Xin Wen
Mengying Cui
Shui Liu- 1Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, China
- 2Department of Clinical Laboratory, The Second Hospital of Jilin University, Jilin University, Changchun, China
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death worldwide. Treatment of HCC has shifted from traditional modalities to immunotherapy-centered combination strategies. While the current immunotherapies can substantially reduce the risk of death for patients with HCC, overall survival improvement is limited because of tumor heterogeneity and an immunosuppressive microenvironment. Moreover, the widespread application of these treatments is challenged by high costs, drug resistance, and frequent adverse events. This review outlines the mechanisms of the available HCC immunotherapeutics and summarizes the preclinical explorations of these treatments. We also describe the current clinical applications and underlying mechanisms and discuss issues of resistance and heterogeneity. We further provide an overview of emerging approaches against cancer platforms in HCC, aiming to provide practical references for clinical immunotherapy of HCC.
1 Introduction
Primary liver cancer is one of common digestive system malignancies, and ranks sixth in incidence and third in mortality among all cancers In the WHO 2022 statistics (1). Hepatocellular carcinoma (HCC) accounting for approximately 75%-85% of all primary liver cancers (2, 3). Currently, curative surgical resection is the only potentially curative option besides liver transplantation for HCC. In recent years, the 5-year survival rate for HCC has improved from less than 18% to 22%, as a result of the development of multimodal treatment frameworks incorporating ablation, transarterial therapies, and tyrosine kinase inhibitors (TKIs) (4). However, outcomes remain concerning for patients with unresectable disease and those at high risk of recurrence. Approximately 70% of HCC patients are first diagnosed at an intermediate or advanced stage, and 50~70% of HCC patients who undergo surgery face a risk of recurrence, which severely compromises prognosis (5).
Since the approval of the immune checkpoint inhibitor (ICI) nivolumab for intermediate-to-advanced HCC (6), immunotherapy has produced breakthrough advances (7). Immunotherapy reduces the risk of death by approximately 22%–43% and extends survival by more than six months on average in HCC (8). However, significant challenges remain. Tumor cells can develop adaptive resistance through epigenetic and metabolic reprogramming (9), and amplification of the adenosine axis and VEGF-mediated immunosuppression within the tumor microenvironment (TME) fosters immune tolerance (10). Moreover, the lack of effective biomarkers hampers drug selection for patients of HCC, and the widely used regimen atezolizumab plus bevacizumab can cause gastrointestinal bleeding, portal hypertension, and hepatic decompensation with appreciable frequency (11). The high cost and less than optimal effectiveness of immunotherapy also limits its application (12).
In the manuscript, we comprehensively describe the mechanisms and current clinical application of immunotherapy for HCC and summarize the preclinical advances, challenges, and potential strategies, with the aim to provide a systematic reference for basic research and clinical practice in this field, facilitate the development and optimization of new immunotherapy regimens, and offer ideas for addressing bottleneck issues in clinical application (such as drug resistance, insufficient efficacy prediction), ultimately improving the prognosis and quality of life of patients with HCC (Figure 1).
Figure 1. Schematic diagram of clinical application and preclinical exploration of immunotherapy for HCC.
2 The antitumor mechanisms of immunotherapy in HCC
2.1 Immune checkpoint inhibitors
Immune checkpoint molecules are pivotal regulators of immune homeostasis and T-cell activity. However, in the tumor TME, the overexpression of inhibitory checkpoints constitutes a primary mechanism of immune evasion (13). This overexpression frequently leads to T-cell exhaustion, thereby facilitating tumor growth. Consequently, immune checkpoint inhibitors have emerged as a critical therapeutic strategy in current cancer treatment (14). The use of immune checkpoint inhibitors (ICIs), such as inhibitors against programmed cell death protein 1(PD-1)/programmed cell death ligand 1 (PD-L1) or cytotoxic T-lymphocyte antigen 4 (CTLA-4), to enhance costimulation and relieve immunosuppression has become a first-line approach for the treatment of many cancers (15). Most HCC cases are accompanied by fibrosis or cirrhosis because of chronic necro-inflammation (10). This pathological background significantly influences immunotherapeutic efficacy. The fibrotic microenvironment acts as a physical barrier that restricts T-cell infiltration, while activated hepatic stellate cells secrete transforming growth factor-beta (TGF-B) to foster an immunosuppressive milieu, thereby limiting the antitumor activity of immune checkpoint inhibitors (16). Moreover, because of the liver’s unique immune microenvironment, the mechanisms of immunotherapy in HCC are particularly complex and distinctive (17) (Figure 2). In HCC tumors, PD-1 is highly expressed on exhausted intratumoral CD8+ T cells; blocking PD-1 interrupts SHP-2 recruitment to phosphorylated ITIM/ITSM motifs, thereby restoring proximal CD3ζ/ZAP70 and CD28 signaling, reinvigorating effector cytokine production and cytotoxicity in HCC T cells, and increasing secretion and effector functions of IL-2 and other cytokines (18). PD-1/PD-L1 blockade in HCC also preserves and expands a TCF1+ progenitor-exhausted CD8+ subset linked to better response potential; this reinvigoration is further enhanced when additional inhibitory axes (e.g., TIGIT) are relieved in ex vivo HCC samples (19). Anti-PD-L1 antibodies exert similar effects. Additionally, the Fc region of some anti-PD-L1 antibodies engages Fcγ receptors to activate natural killer (NK) cells and trigger antibody-dependent cellular cytotoxicity, directly eliminating PD-L1-high tumor cells or suppressive myeloid cells (20). Those anti-PD-L1 antibodies also influence tumor AKT/mTOR signaling, glycolysis, apoptosis, and autophagy and can modulate gene transcription (21).
Figure 2. The antitumor mechanisms of immune checkpoint inhibitors in HCC.
In the HCC TME, enrichment of tumor-infiltrating regulatory T cells (Tregs) together with the upregulation of CTLA-4 collectively attenuate costimulatory signaling. CTLA-4, another receptor on T cells, competes with CD28 for CD80/CD86 on antigen-presenting cells (APCs) and thereby dampens immunostimulatory signaling (22). Anti-CTLA-4 agents block this process and partially restore co-stimulation. Mechanistically, B7 molecules on activated T cells are cleared from the membrane by CTLA-4 in the tumor milieu in HCC (23). Inhibiting CTLA-4 increases both the quantity and quality of activated T cells. Because much of the efficacy of anti-CTLA-4 approaches is derived from Fc-mediated depletion of Tregs (24), molecularly enhancing Fc functions can markedly augment Treg clearance and antitumor responses. LAG-3, another checkpoint molecule expressed on tumor-infiltrating T cells, uses a distinctive geometric configuration to enforce tight membrane spacing between T cells and APCs, thereby impeding immune activation (25). Anti-LAG-3 antibodies disrupt this association, restore TCR/CD4 signaling, and reinstate antigen presentation (26).
2.2 Anti-angiogenic agents
HCC is a highly vascularized tumor. Multiple axes, including VEGF/VEGFR, FGF, PDGF, and Ang/Tie2 signaling, drive endothelial hyperproliferation with poor pericyte coverage, producing an aberrant, leaky, tortuous microvasculature (27). This creates local hypoxia that disables oxygen-dependent therapies; the distorted capillary architecture elevates interstitial pressure and leakage, further impeding drug penetration into the tumor core (28). Anti-VEGF antibodies increase pericyte coverage, reduce permeability, and raise oxygenation (29), thereby improving luminal patency and effective perfusion, lowering interstitial pressure, and increasing the intratumoral concentrations and efficacy of cytotoxics (30). STING agonists also repair abnormal vasculature: by inducing robust type-I interferon and chemokine release, they remodel the TME through mechanisms akin to anti-VEGF therapy, promoting vascular normalization (31). The ability of these agonists to activate APCs and dendritic cells has likewise made them a research focus (32).
2.3 Other immunotherapeutic strategies
Several other anti-tumor mechanisms have gained attention as potential therapeutic targets in recent years. B cells are key constituents of the TME and closely linked to tertiary lymphoid structures (TLS) within tumors (33). Clonal expansion and affinity maturation of B cells within TLS synergize with enhanced CD8+ T-cell effector functions; TLS-rich tumors tend to mount more active immune responses (34). The combination of FOLFOX-HAIC with immune checkpoint blockade can remodel the TME and promote TLS formation (35). However, the relationship between dynamic TLS changes and treatment outcomes in HCC requires confirmation in larger cohorts or experimental studies.
Hepatic Kupffer cells, sinusoidal endothelial cells, and dendritic cells are sensitive to metabolites from the gut microbiota, especially secondary bile acids, which can positively influence responses to immune checkpoint inhibitors (36). Probiotics and healthy microbiota enhance APC function, upregulate CXCL9/10 and adhesion molecules, and facilitate CD8+ T-cell infiltration into tumors (37). These results suggest that dietary modulation may confer therapeutic benefits in HCC.
3 Current immunotherapy for HCC in clinical
3.1 Immune checkpoint inhibitors
PD1 inhibitors and PD-L1 inhibitors, as the core of currently recommended treatment regimens for HCC, are mostly used in combination therapies. The combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (an anti-VEGF agent) has become a first-line treatment for unresectable advanced HCC (38). Their complementary functions in relieving immunosuppression enable them to achieve a synergistic effect in practical application, establishing this combination as the first-line treatment standard for advanced unresectable HCC (39).
The combination of PD1 inhibitors with anti-angiogenic agents also yields positive effects. The combination of camrelizumab and rivoceranib synergistically enhances immune function and repairs the microenvironment (40, 41). An additional advantage of this treatment is that vascular normalization promotes the formation of TLS, allowing continuous infiltration of peripheral T cells into tumors, which consolidates treatment efficacy and improves prognosis (42). Some multi-target TKIs have unique effects. Lenvatinib downregulates the Treg/TAM pathway and enhances the IFN-I antigen presentation pathway (43). However, its clinical application scope is narrower than that of bevacizumab, so it is recommended as an alternative treatment. Cabozantinib is similar in this regard: in addition to its anti-angiogenic role, it also interferes with the immunosuppressive loop of MET/AXL-myeloid-epithelial-mesenchymal transition (44). However, phase III clinical results for cabozantinib in HCC show unstable survival benefits (45). Notably, not all combinations of PD1/PD-L1 inhibitors with anti-angiogenic agents achieve favorable outcomes; excessive vascular reduction may occur when some highly potent TKIs are used or when the treatment sequence is incorrect (46), offsetting the synergistic effect with immune checkpoint inhibitors. Therefore, in clinical drug selection, in addition to efficacy, factors such as the patient’s genotype, biological matching degree, treatment timing and dosage, and the impact of subsequent treatment on the current regimen should be considered (47).
CTLA-4 increases the number of naïve lymphocytes, so it can complement immune checkpoint inhibitors (8). Clinically, a high single dose of tremelimumab combined with regular durvalumab is commonly used. This treatment does not directly affect blood vessels, and thus it is suitable for patients at high risk of bleeding or those ineligible for anti-VEGF therapy (48). It is also one of the most commonly used combinations in clinical practice.
The combination of immune checkpoint inhibitors and other treatment regimens, such as transarterial chemoembolization (TACE), is also widely used in clinical practice (49). TACE enhances antigen presentation and alleviates hypoxia by improving perfusion, facilitating T-cell infiltration (50). Durvalumab combined with TACE has significant advantages over ablation alone or immune checkpoint inhibitors alone; anti-VEGF agents can also be added to enhance the synergistic effect when necessary (51). This treatment regimen is often used in cases where local treatment is possible but the tumor burden is large (52). Another retrospective analysis by Rui Zhu et al. showed that Combination therapy regimen of rivoceranib-camrelizumab with TACE achieved significantly higher partial (39.8% vs. 20.2%, P = 0.006) and objective response rates (50.6% vs. 29.7%, P = 0.006) than systemic therapy alone (53). Similar to other combination therapies, attention should be paid to the rationality of treatment timing and subsequent treatment.
3.2 Chimeric antigen receptor T-cell immunotherapy
Chimeric antigen receptor T(CAR-T) - cell immunotherapy, which reprograms T cells to recognize antigens independently of MHC, has revolutionized the treatment of hematologic malignancies. Although its application in solid tumors is challenged by the immunosuppressive TME and physical barriers, CAR-T therapy targeting liver-specific antigens has emerged as a promising strategy for HCC (54). Since the expression of glypican-3 (GPC3) in HCC cells is significantly higher than that in normal liver tissue (55). GPC3-targeting CAR-T cell therapy has high specificity and good safety, and it is currently used in some specific clinical scenarios. In clinical practice, CAR-T cells are usually modified for tumor treatment. CAR-T cells engineered to overexpress the transcription factor RUNX3 (which is associated with immune memory) prolong the retention these CAR-T cells (specifically CT017) in tumor tissue without significant safety differences (56). Conjugating alpha-fetoprotein (AFP, an intracellular antigen) to CAR-T cells to form a dual-antigen-targeting CAR-T cell therapy significantly expanded the killing range of the drug, extending the recognized antigens from the cell surface to the intracellular space (57). However, this approach entails inherent safety risks, particularly the potential for ‘on-target, off-tumor’ toxicity in regenerating hepatocytes that transiently express AFP, or cross-reactivity with similar peptides presented on the surface of vital organs. Therefore, more specific antigens need to be identified in clinical practice to avoid damage to normal tissue. Additionally, the modification of CAR-T cells with CD133 not only enhances tumor killing but also affects angiogenesis, influencing tumor blood supply and invasion (58), which can fundamentally reverse HCC drug resistance. However, clinical application of this therapy is challenging because of its low specificity, as CD133 is also expressed in normal hepatocytes.
Combining CAR-T cell therapy with other treatment regimens is also an option in clinical treatment. TACE can induce tumor cells to release a large number of surface antigens, and the increased antigen supply provides sufficient signals for CAR-T cell therapy (59), enhancing its targeting effect. Immune checkpoint inhibitors can also be added to assist treatment when necessary. While the application of CAR-T cell therapy and inhibitors in HCC is more difficult than in other tumors because of the unique TME (60), satisfactory clinical effects can still be achieved through modifying the drugs themselves or combining them with other regimens. However, these treatment regimens require careful design and strict evaluation for clinical application.
3.3 Other immunotherapeutic strategies
In addition to the widely used regimens mentioned above, several cutting-edge immunotherapies have also shown clinical potential. Cancer vaccines have been engineered to deliver specific antigens expressed on HCC cells via platforms such as DNA or peptides (61). These antigen vaccines have strong adaptability and can be combined with various other treatment regimens. For example, the combination of an antigen vaccine with interleukin-12 (IL-12) plasmid and pembrolizumab achieved an objective response rate of 30%, significantly enhancing tumor-specific immune capacity and improving clinical response (62). During local treatment, antigen vaccines also enhance cross-presentation and antigen-specific responses (such as responses to AFP), thereby improving treatment benefits (63).
NK cell therapy, which involves the infusion of autologous or allogeneic NK cells or cytokine-sensitized NK cells, also has clinical activity and high safety (64). This regimen is particularly effective for patients with T-cell exhaustion or strong immunosuppression. For patients with poor liver function or advanced HCC during the peri-interventional period, the infusion of invariant NK T cells can result in rapid secretion of interferon-gamma (IFN-γ), activation of dendritic cells and NK cells, reshaping of myeloid suppression, and significantly improvement in patients’ quality of life (65). The combination of oncolytic viruses injected into tumor tissue or via the hepatic artery with TACE can result in tumor cell lysis while enhancing immunity; this is also an innovative clinical treatment method used during the peri-interventional period (66).
4 Preclinical exploration
4.1 Unvalidated combination therapy regimens
While clinical applications have established standard regimens, preclinical research and early-phase trials focus on addressing unmet needs such as drug resistance and limited applicability (Table 1). In addition to the first-line therapy of atezolizumab plus bevacizumab, which can significantly improve OS compared with sorafenib (39), the combination of camrelizumab and rivoceranib also significantly prolongs patient survival (67). Supported by the phase III Cares-310 trial, this combination achieves a median OS of 22.1 months versus 15.2 months for sorafenib, with vascular normalization as a key mechanism enhancing T-cell infiltration (67).It is preferred for patients with intermediate liver function (Child-Pugh A/B7), especially those with vascular invasion but low bleeding risk (e.g., no active varices). For NASH-related HCC, which is often associated with metabolic disorders and a “cold” TME, the anti-angiogenic effect of rivoceranib may better remodel the immunosuppressive microenvironment compared to other TKIs (45). The 4-year OS update from the HIMALAYA trial confirms durable survival benefit, with a 31% 4-year OS rate in the tremelimumab (single high dose) + durvalumab group (68). This regimen is the first choice for patients at high risk of bleeding (e.g., active varices, recent gastrointestinal bleeding) or those ineligible for anti-VEGF therapy. It also shows promising efficacy in HCV-related HCC, possibly due to CTLA-4 blockade-induced depletion of Tregs in virus-associated inflammatory microenvironments (10).
Table 1. The current advances of ICIs for HCC based on clinical trials.
However, not all evaluated drugs have achieved the therapeutic goals. For example, the combination of lenvatinib and pembrolizumab did not significantly improve OS or progression-free survival (PFS) (69). While the combination of cabozantinib and atezolizumab resulted in improved PFS, it did not improve OS (70). Even when combined with local ablation therapy, the combination of durvalumab and bevacizumab only increased PFS compared with TACE alone, but whether OS changes remain under follow-up observation (71). Additionally, some regimens have not yet passed full phase III clinical trials. While they cannot be temporarily used in actual clinical treatment, they can provide new ideas for researchers. Yau et al. discovered the therapeutic potential of the nivolumab plus cabozantinib combination through early exploration (72). The researchers also found that the combination of nivolumab and ipilimumab alleviates symptoms in patients who have received previous treatment (73). Xu et al. confirmed the favorable safety and efficacy of the camrelizumab plus apatinib combination in a phase II single-arm clinical trial (74).
Despite the increase in research on new combination therapy strategies, some of these treatments are associated with safety issues (75). Therefore, some drugs not yet recommended by HCC treatment guidelines also deserve attention, as they have the potential to be combined with immune checkpoint inhibitors. Histological evidence has shown that high expression of LAG-3 is associated with poor prognosis in HCC (76). Guo et al. found that inhibiting the fibrinogen-like protein 1 (FGL1)-LAG-3 axis produces complementary effects with PD-1/PD-L1 inhibitors (77), and this strategy has therapeutic potential for HCC. Sun et al. found that the platelet-mediated CD155-TIGIT signaling enables circulating tumor cells to escape the killing effect of NK cells, which indicates that TIGIT blockade can inhibit the immune evasion of tumor cells (78). Hsiehchen et al. further found that the combination of TIGHT pathway-related interventions with PD-1 inhibitors alleviates the dual-pathway inhibition of T cells and NK cells (79). This regimen has demonstrated clinical feasibility and promising antitumor activity, thus having the potential to solve the problem of immune resistance in HCC.
4.2 Novel targets and pathways for immunotherapy
In addition to these attempts to expand treatments based on existing combination regimens, some research teams are conducting clinical trials on treatments based on other mechanisms of action. Extending the findings that C-X-C chemokine receptor type 2 (CXCR2) alleviates immunosuppression when combined with immune checkpoint inhibitors through the neutrophil/macrophage axis, Myojin et al. speculated that the combination of inhibitors against adenosine A2A receptor (A2A) and anti-PD-1 agents might produce a strong synergistic effect in suppressing tumor growth and prolonging survival (80), which might target NASH-related HCC patients with high adenosine levels (indicated by elevated plasma adenosine concentration), who often respond poorly to conventional ICI therapy. This combination also has an independent antitumor function in non-alcoholic steatohepatitis-related HCC.
The discovery that ferroptosis in tumor cells can alleviate immunosuppression has also attracted attention. Cheu et al. proposed the following strategy: triggering ferroptosis through inhibitors targeting ferroptosis suppressor protein 1 (FSP1), upregulating antigen presentation by dendritic cells/macrophages and T-cell effector function, and combining this approach with PD-1/PD-L1 inhibitors or CD40 agonists to significantly prolong survival (81). Meng et al. triggered ferroptosis by injecting a composite hydrogel of imipenem and sulfasalazine; when combined with anti-PD-1 agents, this treatment significantly alleviated symptoms and induced immune memory in murine HCC models with malignant ascites (82). Wu et al. found that gut microbiome biomarkers are associated with the response of patients with HCC to anti-PD-1-based immunotherapy (83). This discovery provides a direct link between the gut microbiome and immunotherapy outcome, offering new possibilities for non-invasive biomarker candidates to predict therapeutic efficacy.
Several studies on other targets and pathways have yielded promising possibilities. A recent study by the team led by Huang et al. identified that HHLA2 activates the c-Met signaling pathway, thereby serving as a potential therapeutic target and providing a rationale for designing new combination therapies (84). Through studying the important role of triggering receptor expressed on myeloid cells 2 (TREM) in the immunosuppressive mechanism of nonalcoholic steatohepatitis-related HCC, Wang et al. confirmed that targeting TREM2 can alleviate immunosuppression in steatohepatitis and exert a synergistic effect with T-cell checkpoint inhibitors (85). Targets such as LAG-3, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15), CD24/Siglec-10, and CD47/signal regulatory protein alpha (SIRPα) can all alleviate immunosuppression in HCC to a certain extent t (86–88).
5 Dilemmas and prospects
5.1 Drug resistance of existing immunotherapies
The expansion of immune checkpoint inhibitors, as the main approach for HCC immunotherapy, and the development of combination treatment regimens have been crucial for the improvements in therapeutic efficacy and outcome for patients with HCC (89). However, there are still dilemmas in clinical application. Drug resistance of HCC to immunotherapy has long been the most critical factor leading to poor clinical efficacy and is classified into primary resistance and acquired resistance. The WNT/B-catenin pathway is a core signaling pathway for human embryonic development and tissue repair (90). Under normal conditions, it regulates cell proliferation and differentiation; however, this pathway is continuously activated in tumor cells and is a mechanism of primary drug resistance (91). This type of resistance alters the TME, making the efficacy of many HCC immunotherapy combination regimens, including atezolizumab plus bevacizumab, far less effective than in other tumors (92). To address this dilemma, the combination of LNP-siRNA targeting B-catenin and immune checkpoint inhibitors can inhibit CTNNB1 to a certain extent, but this approach has issues such as insufficient specificity, making it difficult to apply in actual clinical scenarios (93).
Another mechanism of primary resistance lies in immune exhaustion caused by hypoxia-vascular abnormalities in the TME (94). Hypoxia upregulates PD-L1 via HIF-1α to promote immune escape. Therefore, it is necessary to correct the hypoxia issue during treatment. Vascular changes also play a similar role: VEGF induces dendritic cell maturation disorders and Treg expansion and reduces the responsiveness of endothelial cells (95). This is also a strategy in existing treatment regimens. Overall, the complexity of primary resistance means that treatment strategies need to take many factors into account, often failing to achieve the desired effect.
Acquired resistance is another critical issue that requires attention. The myeloid-dominated immunosuppressive microenvironment is not only associated with primary resistance but may also be associated with acquired resistance. In HCC, SPP1+ macrophages and cancer-associated fibroblasts form an immune barrier, which traps CD8+ T cells outside the tumor nest and significantly reduces the immune response (96). Inhibiting TREM2 enhances the efficacy of anti-PD-L1, indicating that TREM2 is a key target in the inhibitory mechanism (97). The inhibition of the SPP1+ macrophage-stem cell-like tumor axis is currently an approach to address the drug-resistant TME. Intervening in SPP1+ macrophages and TREM2+ macrophages through pharmacological or genetic means has shown good effects in various tumor SPP1+ (98), but its efficacy in HCC still requires further research.
The strong heterogeneity of HCC is another reason for the difficulty in formulating treatment regimens. The copy number variation in HCC conforms to a two-stage model of “interspersed bursts + gradual accumulation”, in which a prolonged phase of gradual accumulation leads to higher tumor heterogeneity and rapid recurrence (99). Early key driver mutations (such as TP53 and CTNNB1 mutations) lay the foundation for different branches of tumor evolution, while late-stage copy number variation and viral integration shape different transcriptional subtypes (100). This explains why it is particularly difficult to formulate reasonable treatment strategies for HCC, especially in the advanced stage.
5.2 Organoid models
To improve the targeting of treatment regimens and reduce drug resistance, the use of cells derived from patient tumor tissues to establish tumor organoids for research has become a hotspot in recent years. This approach facilitates genetic-level intervention in tumor treatment and significantly improves drug efficacy (101). Organoid therapy for brain tissue diseases has achieved wide clinical application (102). A similar biobank has also been established for HCC organoids (103), and some promising results have been achieved in animal model experiments (104). In clinical cases, after administering an individualized combination regimen selected based on patient-derived organoid drug sensitivity results, the tumor shrank significantly, and pathological complete cure was achieved through surgical treatment (105). This indicates that organoid models have the potential to assist in personalized treatment and solve the long-standing problem of the difficulty in determining treatment regimens for HCC because of high heterogeneity. Additionally, co-culturing HCC organoids with endothelial cells can reproduce the vascular changes caused by the upregulation of factors such as MCP-1, IL-8, and CXCL16 in the TME (106). This provides an operable in vitro model for laboratory research on the TME and drug resistance. However, HCC organoid research still has limitations (107). Firstly, liver cancer organoids mainly consist of tumor cells and lack interactions with stromal cells (such as hepatic stellate cells, vascular endothelial cells) and immune cells, thus failing to truly simulate the tumor immune microenvironment, which limits their application in immunotherapy research (108). Secondly, there is currently no unified assessment standard for “mature” or “functionally normal” organoids, nor a unified culture condition, the construction of organoids lacks standardization and quality control (109); thirdly, the construction success rate of organoids is low and unstable, and they can only maintain activity and function for a limited period of time, and there are challenges in terms of cost and scalability (110). Therefore, although organoid models have therapeutic potential, they currently cannot be widely applied in clinical practice.
5.3 Other innovative therapies
Several cutting-edge therapies currently used for other tumors also have therapeutic potential for HCC. Tumor-infiltrating lymphocyte (TIL) therapy has shown high safety for unresectable melanoma and alleviates symptoms even in drug-resistant populations (111). For HCC with a more complex immune environment, the combination of polyclonal TILs with other therapies has therapeutic potential. In prostate cancer and some neuroendocrine tumors of the digestive system, molecular probe-targeted radioligand therapy can significantly prolong overall survival (112). HCC tumors express receptors such as GPC3, ASGPR, and OX40. Consequently, radioligand therapy for HCC may be feasible if highly specific ligands targeting these receptors are identified (113). The TCR-CD3 bispecific immunotherapy for metastatic uveal melanoma also has potential for HCC treatment. After selecting appropriate peptide-HLA targets for HCC, bispecific therapy may also prolong the survival of patients with advanced HCC (114). However, its narrow application range and uncertain toxicity are issues that need to be addressed in subsequent research.
6 Conclusion
The evolution of HCC treatment from traditional modalities to immunotherapy-based combinations represents a paradigm shift, yet clinical outcomes remain constrained by the profound heterogeneity of the tumor and the unique tolerogenic nature of the liver microenvironment. Current evidence underscores that overcoming the limitations of first-line immune checkpoint inhibitors requires a deeper disruption of specific resistance mechanisms. Future therapeutic breakthroughs will likely depend on dismantling the “positive feedback loop” of vascular abnormality, hypoxia, and immunosuppression, as well as targeting the physical and chemical barriers created by SPP1+/TREM2+ macrophages and hepatic stellate cells.
Moving forward, the field must transition from a “one-size-fits-all” approach to precision immuno-oncology. The integration of multi-omics with patient-derived organoid (PDO) drug screening offers a viable framework for constructing companion diagnostics that can predict therapeutic response and guide rational drug selection. Furthermore, the clinical translation of emerging modalities—such as TIL therapy, targeted radioligand therapy (RLT), and TCR-CD3 bispecific platforms—holds the potential to address antigen-loss variants and refractory disease. Ultimately, resolving the bottlenecks of primary and acquired resistance through these multi-dimensional strategies will be key to significantly extending survival and improving the quality of life for patients with advanced HCC.
Author contributions
HY: Writing – original draft, Writing – review & editing, Methodology, Validation, Data curation, Conceptualization, Project administration. XW: Methodology, Validation, Writing – review & editing, Data curation, Project administration, Conceptualization. MC: Writing – review & editing, Methodology, Conceptualization, Project administration. SL: Funding acquisition, Writing – original draft, Conceptualization, Writing – review & editing, Methodology.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This research was funded by Jilin Province Health and Wellness Science and Technology Capacity Enhancement Project (2025WS-KA011) and Natural Science Foundation of Jilin Province (YDZJ202301ZYTS080).
Acknowledgments
We thank authors of the papers published in this research topic for their valuable contributions and the referees for their rigorous review.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, and Jemal A. Cancer statistics, 2025. CA Cancer J Clin. (2025) 75:10–45. doi: 10.3322/caac.21871
2. Qin LX. Immunotherapy for Hepatobiliary Malignancies: Progress and Prospective. Hepatobiliary Pancreat Dis Int (2022) 75:498–527. doi: 10.1016/j.hbpd.2022.09.002
3. Xu FWX, Tang SS, Soh HN, Pang NQ, and Bonney GK. Augmenting care in hepatocellular carcinoma with artificial intelligence. Artif Intell Surg. (2023) 3:48–63. doi: 10.20517/ais.2022.33
4. Cranford HM, Jones PD, Wong RJ, Liu Q, Kobetz EN, Reis IM, et al. Hepatocellular carcinoma etiology drives survival outcomes: A population-based analysis. Cancer Epidemiol Biomarkers Prev. (2024) 33:1717–26. doi: 10.1158/1055-9965.Epi-24-0626
5. Sun J, Xia Y, Shen F, and Cheng S. Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion (2024 edition). Hepatobiliary Surg Nutr. (2025) 14:246–66. doi: 10.21037/hbsn-24-359
6. Saung MT, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M, et al. Fda approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist. (2021) 26:797–806. doi: 10.1002/onco.13819
7. Lei H, Xiang T, Zhu H, and Hu X. A novel cholesterol metabolism-related lncrna signature predicts the prognosis of patients with hepatocellular carcinoma and their response to immunotherapy. Front Biosci (Landmark Ed). (2024) 29:129. doi: 10.31083/j.fbl2903129
8. Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surg Nutr. (2022) 11:592–6. doi: 10.21037/hbsn-22-143
9. Zhang N, Yang X, Piao M, Xun Z, Wang Y, Ning C, et al. Biomarkers and prognostic factors of pd-1/pd-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. biomark Res. (2024) 12:26. doi: 10.1186/s40364-023-00535-z
10. Childs A, Aidoo-Micah G, Maini MK, and Meyer T. Immunotherapy for hepatocellular carcinoma. JHEP Rep. (2024) 6:101130. doi: 10.1016/j.jhepr.2024.101130
11. Zhang X, Wang J, Shi J, Jia X, Dang S, and Wang W. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma. JAMA Netw Open. (2021) 4:e214846. doi: 10.1001/jamanetworkopen.2021.4846
12. Wagle NS and Spencer JC. Challenges for measuring cost-effectiveness of immunotherapy in unresectable hepatocellular carcinoma. JAMA Netw Open. (2021) 4:e215476. doi: 10.1001/jamanetworkopen.2021.5476
13. Mejía-Guarnizo LV, Monroy-Camacho PS, Turizo-Smith AD, and Rodríguez-García JA. The role of immune checkpoints in antitumor response: A potential antitumor immunotherapy. Front Immunol. (2023) 14:1298571. doi: 10.3389/fimmu.2023.1298571
14. Zhao S, Zhao H, Yang W, and Zhang L. The next generation of immunotherapies for lung cancers. Nat Rev Clin Oncol. (2025) 22:592–616. doi: 10.1038/s41571-025-01035-9
15. Tang Z and Veillette A. Inhibitory immune checkpoints in cancer immunotherapy. Sci Immunol. (2025) 10:eadv6870. doi: 10.1126/sciimmunol.adv6870
16. Wang W, Gao Y, Chen Y, Cheng M, Sang Y, Wei L, et al. Tgf-B Inhibitors: the future for prevention and treatment of liver fibrosis? Front Immunol. (2025) 16:1583616. doi: 10.3389/fimmu.2025.1583616
17. Schreiber RD, Old LJ, and Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. (2011) 331:1565–70. doi: 10.1126/science.1203486
18. Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of pd-1/pd-L1 in cancers. Mol Cancer. (2024) 23:108. doi: 10.1186/s12943-024-02023-w
19. Gill AL, Wang PH, Lee J, Hudson WH, Ando S, Araki K, et al. Pd-1 blockade increases the self-renewal of stem-like cd8 T cells to compensate for their accelerated differentiation into effectors. Sci Immunol. (2023) 8:eadg0539. doi: 10.1126/sciimmunol.adg0539
20. Osborne N, Rupani A, Makarov V, Chan TA, and Srivastava RM. Avelumab induces greater fc-fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab. Oncoimmunology. (2025) 14:2494995. doi: 10.1080/2162402x.2025.2494995
21. Liu D, Wen C, Chen L, Ye M, Liu H, Sun X, et al. The emerging roles of pd-L1 subcellular localization in tumor immune evasion. Biochem Pharmacol. (2024) 220:115984. doi: 10.1016/j.bcp.2023.115984
22. Kennedy A, Waters E, Rowshanravan B, Hinze C, Williams C, Janman D, et al. Differences in cd80 and cd86 transendocytosis reveal cd86 as a key target for ctla-4 immune regulation. Nat Immunol. (2022) 23:1365–78. doi: 10.1038/s41590-022-01289-w
23. Xu X, Dennett P, Zhang J, Sherrard A, Zhao Y, Masubuchi T, et al. Ctla4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis. J Exp Med. (2023) 220:e20221391. doi: 10.1084/jem.20221391
24. Knorr DA, Blanchard L, Leidner RS, Jensen SM, Meng R, Jones A, et al. Fcγriib is an immune checkpoint limiting the activity of treg-targeting antibodies in the tumor microenvironment. Cancer Immunol Res. (2024) 12:322–33. doi: 10.1158/2326-6066.Cir-23-0389
25. Wang Z, Zhou T, Wang H, Li H, Zhao W, Wang F, et al. Lag3-mhcii interaction induces a tight cell-cell interface at the immunological synapse. J Immunol. (2025) 214:2256–69. doi: 10.1093/jimmun/vkaf120
26. Ming Q, Antfolk D, Price DA, Manturova A, Medina E, Singh S, et al. Structural basis for mouse lag3 interactions with the mhc class ii molecule I-a(B). Nat Commun. (2024) 15:7513. doi: 10.1038/s41467-024-51930-5
27. Yao C, Wu S, Kong J, Sun Y, Bai Y, Zhu R, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biol Med. (2023) 20:25–43. doi: 10.20892/j.issn.2095-3941.2022.0449
28. Chen Z, Han F, Du Y, Shi H, and Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. (2023) 8:70. doi: 10.1038/s41392-023-01332-8
29. Choi Y and Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. (2023) 55:2308–19. doi: 10.1038/s12276-023-01114-w
30. Qian C, Liu C, Liu W, Zhou R, and Zhao L. Targeting vascular normalization: A promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Front Immunol. (2023) 14:1291530. doi: 10.3389/fimmu.2023.1291530
31. Wang-Bishop L, Kimmel BR, Ngwa VM, Madden MZ, Baljon JJ, Florian DC, et al. Sting-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. Sci Immunol. (2023) 8:eadd1153. doi: 10.1126/sciimmunol.add1153
32. Ribeiro ARS, Neuper T, and Horejs-Hoeck J. The role of sting-mediated activation of dendritic cells in cancer immunotherapy. Int J Nanomedicine. (2024) 19:10685–97. doi: 10.2147/ijn.S477320
33. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, and Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. (2022) 19:441–57. doi: 10.1038/s41571-022-00619-z
34. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. (2020) 577:549–55. doi: 10.1038/s41586-019-1922-8
35. Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, et al. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma. Nat Immunol. (2024) 25:2110–23. doi: 10.1038/s41590-024-01992-w
36. Song Y, Lau HC, Zhang X, and Yu J. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. Cancer Biol Med. (2023) 21:144–62. doi: 10.20892/j.issn.2095-3941.2023.0394
37. Ren S, Zhang Y, Wang X, Su J, Wang X, Yuan Z, et al. Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma. Front Immunol. (2025) 16:1526967. doi: 10.3389/fimmu.2025.1526967
38. Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. (2025) 36:491–506. doi: 10.1016/j.annonc.2025.02.006
39. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. (2020) 382:1894–905. doi: 10.1056/NEJMoa1915745
40. Ye X, Fang X, Li F, and Jin D. Targeting time in advanced hepatocellular carcinoma: mechanisms of drug resistance and treatment strategies. Crit Rev Oncol Hematol. (2025) 211:104735. doi: 10.1016/j.critrevonc.2025.104735
41. Zhao Q, He Y, Nian Z, Huang Y, Huang R, Lai L, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: A cost-utility analysis in China and the United States. Front Pharmacol. (2025) 16:1404389. doi: 10.3389/fphar.2025.1404389
42. Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-pd-L1 therapy stimulates tumor immunity through hev formation. Sci Transl Med. (2017) 9. doi: 10.1126/scitranslmed.aak9679
43. Torrens L, Montironi C, Puigvehí M, Mesropian A, Leslie J, Haber PK, et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. (2021) 74:2652–69. doi: 10.1002/hep.32023
44. Hsu CH, Huang YH, Lin SM, and Hsu C. Axl and met in hepatocellular carcinoma: A systematic literature review. Liver Cancer. (2022) 11:94–112. doi: 10.1159/000520501
45. Msaouel P, Genovese G, Gao J, Sen S, and Tannir NM. Tam kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets. (2021) 25:141–51. doi: 10.1080/14728222.2021.1869212
46. Mpekris F, Panagi M, Charalambous A, Voutouri C, and Stylianopoulos T. Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy. Cell Rep Med. (2024) 5:101626. doi: 10.1016/j.xcrm.2024.101626
47. Wang SL and Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. (2025) 43:641–64. doi: 10.1016/j.ccell.2025.03.006
48. Shin HP and Lee M. Navigating the therapeutic pathway and optimal first-line systemic therapy for hepatocellular carcinoma in the era of immune checkpoint inhibitors. Med (Kaunas). (2025) 61:2164. doi: 10.3390/medicina61122164
49. Liang Y, Yang J, Li H, Wu J, Tan W, Ren Y, et al. Efficacy and safety of tace plus lenvatinib with pd-1 inhibitor for unresectable huge hepatocellular carcinoma: A multicenter retrospective cohort study. Int J Surg. (2025). doi: 10.1097/js9.0000000000004131
50. Singh P, Toom S, Avula A, Kumar V, and Rahma OE. The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. (2020) 7:11–7. doi: 10.2147/jhc.S187121
51. Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (Emerald-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. (2025) 405:216–32. doi: 10.1016/s0140-6736(24)02551-0
52. Brandi N and Renzulli M. The synergistic effect of interventional locoregional treatments and immunotherapy for the treatment of hepatocellular carcinoma. Int J Mol Sci. (2023) 24:11–17. doi: 10.3390/ijms24108598
53. Zhu R, Zhang ZX, Lu XZ, and Mao K. Transarterial chemoembolization with rivoceranib and camrelizumab for bclc stage C hepatocellular carcinoma. Front Oncol. (2025) 15:1710686. doi: 10.3389/fonc.2025.1710686
54. Grieve AP. Pre-posterior distributions in drug development and their properties. Pharm Stat. (2025) 24:e2450. doi: 10.1002/pst.2450
55. Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. (2020) 26:3979–89. doi: 10.1158/1078-0432.Ccr-19-3259
56. Fu Q, Zheng Y, Fang W, Zhao Q, Zhao P, Liu L, et al. Runx-3-expressing car T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: A phase I trial. EClinicalMedicine. (2023) 63:102175. doi: 10.1016/j.eclinm.2023.102175
57. Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, et al. Targeting alpha-fetoprotein (Afp)-mhc complex with car T-cell therapy for liver cancer. Clin Cancer Res. (2017) 23:478–88. doi: 10.1158/1078-0432.Ccr-16-1203
58. Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of cd133-directed car T cells in advanced hepatocellular carcinoma: A single-arm, open-label, phase ii trial. Oncoimmunology. (2020) 9:1846926. doi: 10.1080/2162402x.2020.1846926
59. Shi Y, Shi D, Chi J, Cui D, Tang X, Lin Y, et al. Combined local therapy and car-gpc3 T-cell therapy in advanced hepatocellular carcinoma: A proof-of-concept treatment strategy. Cancer Commun (Lond). (2023) 43:1064–8. doi: 10.1002/cac2.12472
60. Peng L, Sferruzza G, Yang L, Zhou L, and Chen S. Car-T and car-nk as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. (2024) 21:1089–108. doi: 10.1038/s41423-024-01207-0
61. Fan T, Zhang M, Yang J, Zhu Z, Cao W, and Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. (2023) 8:450. doi: 10.1038/s41392-023-01674-3
62. Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1/2 trial. Nat Med. (2024) 30:1044–53. doi: 10.1038/s41591-024-02894-y
63. Ma YT, Zuo J, Kirkham A, Curbishley S, Blahova M, Rowe AL, et al. Addition of dendritic cell vaccination to conditioning cyclophosphamide and chemoembolization in patients with hepatocellular carcinoma: the immunotace trial. Clin Cancer Res. (2025) 31:3412–23. doi: 10.1158/1078-0432.Ccr-25-0142
64. Tavakoli S, Samareh-Salavati M, Rahnama MA, Abdolahi S, Hassanzadeh A, Ghazvinian Z, et al. Natural killer cell therapy in hepatocellular carcinoma: A comprehensive review. Discov Oncol. (2025) 16:1348. doi: 10.1007/s12672-025-03138-2
65. Guo J, Bao X, Liu F, Guo J, Wu Y, Xiong F, et al. Efficacy of invariant natural killer T cell infusion plus transarterial embolization vs transarterial embolization alone for hepatocellular carcinoma patients: A phase 2 randomized clinical trial. J Hepatocell Carcinoma. (2023) 10:1379–88. doi: 10.2147/jhc.S416933
66. Mirbahari SN, Da Silva M, Zúñiga AIM, Kooshki Zamani N, St-Laurent G, Totonchi M, et al. Recent progress in combination therapy of oncolytic vaccinia virus. Front Immunol. (2024) 15:1272351. doi: 10.3389/fimmu.2024.1272351
67. Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (Cares-310): A randomised, open-label, international phase 3 study. Lancet. (2023) 402:1133–46. doi: 10.1016/s0140-6736(23)00961-3
68. Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase iii himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. (2024) 35:448–57. doi: 10.1016/j.annonc.2024.02.005
69. Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (Leap-002): A randomised, double-blind, phase 3 trial. Lancet Oncol. (2023) 24:1399–410. doi: 10.1016/s1470-2045(23)00469-2
70. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (Cosmic-312): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. (2022) 23:995–1008. doi: 10.1016/s1470-2045(22)00326-6
71. Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/ii study. J Clin Oncol. (2021) 39:2991–3001. doi: 10.1200/jco.20.03555
72. Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the checkmate 040 trial. J Clin Oncol. (2023) 41:1747–57. doi: 10.1200/jco.22.00972
73. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. (2020) 6:e204564. doi: 10.1001/jamaoncol.2020.4564
74. Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (Rescue): A nonrandomized, open-label, phase ii trial. Clin Cancer Res. (2021) 27:1003–11. doi: 10.1158/1078-0432.Ccr-20-2571
75. Postow MA, Sidlow R, and Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. (2018) 378:158–68. doi: 10.1056/NEJMra1703481
76. Li L and Cheng Q. Mxene based nanocomposite films. Explor (Beijing). (2022) 2:20220049. doi: 10.1002/exp.20220049
77. Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z, et al. Expression and clinical significance of lag-3, fgl1, pd-L1 and cd8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. (2020) 18:306. doi: 10.1186/s12967-020-02469-8
78. Sun Y, Li T, Ding L, Wang J, Chen C, Liu T, et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint cd155-tigit. Hepatology. (2025) 81:791–807. doi: 10.1097/hep.0000000000000934
79. Hsiehchen D, Kainthla R, Kline H, Siglinsky E, Ahn C, and Zhu H. Dual tigit and pd-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-pd-1 therapies: the phase 2 liverti trial. Nat Commun. (2025) 16:5819. doi: 10.1038/s41467-025-60757-7
80. Myojin Y, McCallen JD, Ma C, Bauer KC, Ruf B, Benmebarek MR, et al. Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-pd1 treatment in murine hepatobiliary cancers. JHEP Rep. (2024) 6:100959. doi: 10.1016/j.jhepr.2023.100959
81. Cheu JW, Lee D, Li Q, Goh CC, Bao MH, Yuen VW, et al. Ferroptosis suppressor protein 1 inhibition promotes tumor ferroptosis and anti-tumor immune responses in liver cancer. Cell Mol Gastroenterol Hepatol. (2023) 16:133–59. doi: 10.1016/j.jcmgh.2023.03.001
82. Meng J, Yang X, Huang J, Tuo Z, Hu Y, Liao Z, et al. Ferroptosis-enhanced immunotherapy with an injectable dextran-chitosan hydrogel for the treatment of Malignant ascites in hepatocellular carcinoma. Adv Sci (Weinh). (2023) 10:e2300517. doi: 10.1002/advs.202300517
83. Wu H, Zheng X, Pan T, Yang X, Chen X, Zhang B, et al. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-pd-1 based immunotherapy in hepatocellular carcinoma. Int J Cancer. (2022) 151:1321–34. doi: 10.1002/ijc.34118
84. Huang X, Fang R, Pang Y, Zhang Z, Huang J, Li Y, et al. Hhla2 activates C-met and identifies patients for targeted therapy in hepatocellular carcinoma. J Exp Clin Cancer Res. (2025) 44:153. doi: 10.1186/s13046-025-03407-6
85. Wang Z, Zhang Y, Li X, Xia N, Han S, Pu L, et al. Targeting myeloid trem2 reprograms the immunosuppressive niche and potentiates checkpoint immunotherapy in nash-driven hepatocarcinogenesis. Cancer Immunol Res. (2025) 13:1516–32. doi: 10.1158/2326-6066.Cir-24-1088
86. Eghbali S and Heumann TR. Next-generation immunotherapy for hepatocellular carcinoma: mechanisms of resistance and novel treatment approaches. Cancers (Basel). (2025) 17:236. doi: 10.3390/cancers17020236
87. Sheng K, Wu Y, Lin H, Fang M, Xue C, Lin X, et al. Transcriptional regulation of siglec-15 by ets-1 and ets-2 in hepatocellular carcinoma cells. Int J Mol Sci. (2023) 24:792. doi: 10.3390/ijms24010792
88. Makala H, Sheehan-Klenk J, Lee W, Chung JY, Baidoo KE, Nambiar D, et al. Cd24 as a novel radiopharmaceutical target for hepatocellular carcinoma. J Nucl Med. (2025) 66:1400–5. doi: 10.2967/jnumed.125.270167
89. Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. J Clin Oncol. (2024) 42:1830–50. doi: 10.1200/jco.23.02745
90. Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/B-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. (2022) 7:3. doi: 10.1038/s41392-021-00762-6
91. Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, and Chen X. B-catenin signaling in hepatocellular carcinoma. J Clin Invest. (2022) 132:3. doi: 10.1172/jci154515
92. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. (2022) 28:1599–611. doi: 10.1038/s41591-022-01868-2
93. Lehrich BM, Delgado ER, Yasaka TM, Liu S, Cao C, Liu Y, et al. Precision targeting of B-catenin induces tumor reprogramming and immunity in hepatocellular cancers. Nat Commun. (2025) 16:5009. doi: 10.1038/s41467-025-60457-2
94. Chen ZQ, Zuo XL, Cai J, Zhang Y, Han GY, Zhang L, et al. Hypoxia-associated circprdm4 promotes immune escape via hif-1α Regulation of pd-L1 in hepatocellular carcinoma. Exp Hematol Oncol. (2023) 12:17. doi: 10.1186/s40164-023-00378-2
95. Li W, Li GC, Luo CS, Yu QF, and Cui M. Angiogenesis and immunosuppressive niche in hepatocellular carcinoma: reshaping vascular - immune axis to potentiate antipd - 1/pd - L1 therapy. Cancer Manag Res. (2025) 17:2245–59. doi: 10.2147/cmar.S537930
96. Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, et al. Identification of a tumour immune barrier in the hcc microenvironment that determines the efficacy of immunotherapy. J Hepatol. (2023) 78:770–82. doi: 10.1016/j.jhep.2023.01.011
97. Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. Trem2(+) macrophages suppress cd8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. (2023) 79:126–40. doi: 10.1016/j.jhep.2023.02.032
98. Jiang W, Liu L, Xu Z, Qiu Y, Zhang B, Cheng J, et al. Spp1+ Tumor-associated macrophages drive immunotherapy resistance via cd8+ T-cell dysfunction in clear-cell renal cell carcinoma. Cancer Immunol Res. (2025) 13:1533–46. doi: 10.1158/2326-6066.Cir-24-1146
99. Guo L, Yi X, Chen L, Zhang T, Guo H, Chen Z, et al. Single-cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma. Gastroenterology. (2022) 162:238–52. doi: 10.1053/j.gastro.2021.08.052
100. Chen J, Kaya NA, Zhang Y, Kendarsari RI, Sekar K, Lee Chong S, et al. A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and ‘Bad apple’ Effect on clinical trajectory. J Hepatol. (2024) 81:667–78. doi: 10.1016/j.jhep.2024.05.017
101. Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, et al. Organoids: the current status and biomedical applications. MedComm (2020). (2023) 4:e274. doi: 10.1002/mco2.274
102. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. (2013) 501:373–9. doi: 10.1038/nature12517
103. Yang H, Cheng J, Zhuang H, Xu H, Wang Y, Zhang T, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell. (2024) 42:535–51.e8. doi: 10.1016/j.ccell.2024.03.004
104. Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, et al. Raf inhibitor plx8394 selectively disrupts braf dimers and ras-independent braf-mutant-driven signaling. Nat Med. (2019) 25:284–91. doi: 10.1038/s41591-018-0274-5
105. He YG, Wang Z, Li J, Xi W, Zhao CY, Huang XB, et al. Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report. World J Gastrointest Oncol. (2024) 16:4506–13. doi: 10.4251/wjgo.v16.i11.4506
106. Lim JTC, Kwang LG, Ho NCW, Toh CCM, Too NSH, Hooi L, et al. Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment. Biomaterials. (2022) 284:121527. doi: 10.1016/j.biomaterials.2022.121527
107. Zhu X, Trehan R, and Xie C. Primary liver cancer organoids and their application to research and therapy. J Natl Cancer Cent. (2024) 4:195–202. doi: 10.1016/j.jncc.2024.06.002
108. Mo J, Gong D, Zhai M, Yang J, Li Z, Wu M, et al. The application of liver cancer organoids in tumour precision medicine: A comprehensive review. Iliver. (2025) 4:100179. doi: 10.1016/j.iliver.2025.100179
109. Nitaramorn N, Kulkeaw K, and Imwong M. Experimental models of liver-stage malaria: progress, gaps, and challenges. PloS Pathog. (2025) 21:e1013796. doi: 10.1371/journal.ppat.1013796
110. Sljukic A, Green Jenkinson J, Niksic A, Prior N, and Huch M. Advances in liver and pancreas organoids: how far we have come and where we go next. Nat Rev Gastroenterol Hepatol. (2026) 23:44–64. doi: 10.1038/s41575-025-01116-1
111. Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, et al. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). (2025) 45:1229–34. doi: 10.1002/cac2.70050
112. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-psma-617 for metastatic castration-resistant prostate cancer. N Engl J Med. (2021) 385:1091–103. doi: 10.1056/NEJMoa2107322
113. Bartos A and Sikora J. Bioinorganic modulators of ferroptosis: A review of recent findings. Int J Mol Sci. (2023) 24:3634. doi: 10.3390/ijms24043634
114. Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. (2021) 385:1196–206. doi: 10.1056/NEJMoa2103485
115. Sangro B, Qin S, Kelley RK, Wang W, Chan SL, Zhang M, et al. 1494p pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (Pts) with unresectable hepatocellular carcinoma (Uhcc) from the combined China extension and global cohorts in the phase iii himalaya study. Ann Oncol. (2025) 36:S896–S7. doi: 10.1016/j.annonc.2025.08.2124
116. Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (Checkmate 9dw): an open-label, randomised, phase 3 trial. Lancet. (2025) 405:1851–64. doi: 10.1016/s0140-6736(25)00403-9
117. Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (Ibi305) versus sorafenib in unresectable hepatocellular carcinoma (Orient-32): A randomised, open-label, phase 2–3 study. Lancet Oncol. (2021) 22:977–90. doi: 10.1016/s1470-2045(21)00252-7
118. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (Checkmate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. (2022) 23:77–90. doi: 10.1016/s1470-2045(21)00604-5
119. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: A randomized, double-blind, phase iii trial. J Clin Oncol. (2020) 38:193–202. doi: 10.1200/jco.19.01307
120. Shi Y, Han G, Zhou J, Shi X, Jia W, Cheng Y, et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (Hepatorch): A randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. (2025) 10:658–70. doi: 10.1016/s2468-1253(25)00059-7
Keywords: antitumor mechanisms, clinical applications, hepatocellular carcinoma, immunotherapy, preclinical exploration
Citation: Yu H, Wen X, Cui M and Liu S (2026) Preclinical exploration and current clinical applications of immunotherapeutic strategies for hepatocellular carcinoma. Front. Immunol. 17:1769251. doi: 10.3389/fimmu.2026.1769251
Received: 16 December 2025; Accepted: 26 January 2026; Revised: 09 January 2026;
Published: 10 February 2026.
Edited by:
Jun Li, Shanghai Jiao Tong University, ChinaReviewed by:
Zeynep Akbulut, Maltepe University, TürkiyeTao Zhang, Department of HPB of PLA General Hospital, China
Copyright © 2026 Yu, Wen, Cui and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shui Liu, bGl1c2h1aUBqbHUuZWR1LmNu